Glenmark Pharma gets tentative nod from USFDA for acne treatment drug
PTI, Jun 20, 2019, 11:56 AM IST
New Delhi: Glenmark Pharmaceuticals Thursday it has received tentative approval from the US health regulator for Clindamycin Phosphate Foam, used to treat acne.
The approved product is a generic version of Mylan Pharmaceuticals’ Evoclin Foam.
Glenmark Pharmaceuticals, USA, has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1 per cent, the company said in a BSE filing.
For the 12 months to April 2019, Evoclin Foam market achieved annual sales of approximately USD 17 million, Glenmark said, citing IQVIA sales data.
The company’s current portfolio consists of 156 products authorised for distribution at the US marketplace and 59 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA.
The company’s stock was trading 0.21 per cent lower at Rs 508.50 apiece on BSE.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
RBI bars Kotak Mahindra Bank from onboarding new customers via online, issuing fresh credit cards
Reverse migration has begun, says FM Nirmala Sitharaman
Markets sustain winning streak — Sensex jumps over 560 points, Nifty tops 22,300-level
Sensex climbs 640 points, Nifty tops 22,300-level in early trade
Insurance regulator IRDAI abolishes age restriction on health insurance product
MUST WATCH
Latest Additions
“Modi & Shah are sellers and Ambani-Adani are buyers”: Kharge’s sharp attack on BJP-led Centre
Uddhav fires ‘Bogus Janata Party’ barb at BJP over ‘nakli’ Shiv Sena jibe
Deve Gowda slams Rahul Gandhi over ‘wealth redistribution’ promise
LS Polls 2024: Nitin Gadkari faints during campaign rally in Yavatmal
Udupi: BJP Yuva Morcha leaders booked for unauthorised poster campaign